Halozyme Therapeutics (HALO) Cash & Current Investments (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash & Current Investments data on file, last reported at $318.6 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 57.4% year-over-year to $318.6 million in Q1 2026; TTM through Mar 2026 was $318.6 million, a 57.4% decrease from a year earlier, with the FY2025 full-year figure at $142.8 million, down 76.04% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $318.6 million, up from $142.8 million in the prior quarter.
• Over the last five years, Cash & Current Investments for HALO reached as high as $786.1 million in Q1 2022 and fell as low as $142.8 million in Q4 2025.
• Historically, Cash & Current Investments has averaged $457.7 million across 5 years, with a median of $463.5 million in 2024.
• Across the five-year window, Cash & Current Investments jumped 81.97% in 2023 and sank 76.04% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $362.8 million in 2022, then retreated by 7.39% to $336.0 million in 2023, then jumped by 77.4% to $596.1 million in 2024, then sank by 76.04% to $142.8 million in 2025, then surged by 123.09% to $318.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $318.6 million in Q1 2026, $142.8 million in Q4 2025, and $702.0 million in Q3 2025.